NCT02201004 - TOFO Insulin Combination Trial | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

October 31, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

TOFOGLIFLOZIN CSG452

Pharmaceutical form:tablet Route of administration: oral

DRUG

insulin

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

placebo

Pharmaceutical form:tablet Route of administration: oral

Trial Locations (30)

Unknown

Investigational Site Number 392-028, Adachi-ku

Investigational Site Number 392-007, Atsugi-shi

Investigational Site Number 392-026, Chuoh-ku

Investigational Site Number 392-021, Fukuoka

Investigational Site Number 392-002, Ichihara-shi

Investigational Site Number 392-012, Iruma-shi

Investigational Site Number 392-003, Kawaguchi-shi

Investigational Site Number 392-014, Kitakyusyu-shi

Investigational Site Number 392-027, Kobe

Investigational Site Number 392-004, Koga-shi

Investigational Site Number 392-022, Kunitachi-shi

Investigational Site Number 392-019, Kurume-shi

Investigational Site Number 392-001, Kyoto

Investigational Site Number 392-024, Kyoto

Investigational Site Number 392-006, Matsudo-shi

Investigational Site Number 392-008, Mito

Investigational Site Number 392-030, Musashino-shi

Investigational Site Number 392-029, Okayama

Investigational Site Number 392-017, Ōtsu

Investigational Site Number 392-011, Sagamihara-shi

Investigational Site Number 392-020, Sakaishi

Investigational Site Number 392-010, Sapporo

Investigational Site Number 392-016, Sendai

Investigational Site Number 392-018, Shinjuku-ku

Investigational Site Number 392-005, Shizuoka

Investigational Site Number 392-031, Suita-shi

Investigational Site Number 392-015, Sumida-ku

Investigational Site Number 392-023, Sunto-gun

Investigational Site Number 392-013, Tokorozawa-shi

Investigational Site Number 392-025, Yokohama